Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other financing activities (2020 - 2022)

UroGen Pharma's Other financing activities history spans 3 years, with the latest figure at $16000.0 for Q3 2022.

  • For Q3 2022, Other financing activities fell 86.21% year-over-year to $16000.0; the TTM value through Jun 2023 reached $16000.0, down 94.22%, while the annual FY2022 figure was $160000.0, 11.11% up from the prior year.
  • Other financing activities reached $16000.0 in Q3 2022 per URGN's latest filing, down from $55000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $203000.0 in Q1 2020 to a low of $11000.0 in Q4 2020.
  • Average Other financing activities over 3 years is $64750.0, with a median of $36000.0 recorded in 2021.
  • The largest YoY upside for Other financing activities was 400.0% in 2022 against a maximum downside of 86.21% in 2022.
  • A 3-year view of Other financing activities shows it stood at $11000.0 in 2020, then skyrocketed by 54.55% to $17000.0 in 2021, then decreased by 5.88% to $16000.0 in 2022.
  • Per Business Quant, the three most recent readings for URGN's Other financing activities are $16000.0 (Q3 2022), $55000.0 (Q2 2022), and $89000.0 (Q1 2022).